Cover Image

全球皮膚癌症疫苗市場與開發平台分析 (2015年)

Global Skin Cancer Vaccine Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 324740
出版日期 內容資訊 英文 178 Pages
商品交期: 最快1-2個工作天內
Back to Top
全球皮膚癌症疫苗市場與開發平台分析 (2015年) Global Skin Cancer Vaccine Market & Pipeline Insight 2015
出版日期: 2015年02月20日 內容資訊: 英文 178 Pages



第1章 癌症疫苗概要

第2章 癌症疫苗:機制與創新

  • 個體遺傳型癌症疫苗的機制
  • 細胞癌症疫苗的機制
  • 基於醣脂化合物抗原的癌症疫苗機制
  • 腫瘤宿主相互作用癌症疫苗的機制

第3章 皮膚癌症疫苗概要

第4章 皮膚癌症疫苗的機制

第5章 全球皮膚癌症疫苗市場概要

  • 目前市場方案
  • 全球皮膚癌症疫苗開發平台概要

第6章 全球皮膚癌症疫苗的市場動態

  • 推動市場要素
  • 商品化的課題

第7章 各個癌症疫苗:進展和可能性

第8章 全球皮膚癌症疫苗市場未來發展預測

第9章 全球皮膚癌症疫苗開發平台:各企業,Phase別

  • 前臨床
  • 臨床
  • 第一階段
  • 第I/II相
  • 第二階段
  • 第三階段

第10章 推出的皮膚癌症疫苗臨床分析

  • Melanoma Vaccine

第11章 開發中斷/中止的皮膚癌症疫苗開發平台:各企業,Phase別

  • 無開發報告
  • 中止

第12章 競爭情形

  • Amgen
  • AVAX Technologies
  • Corixa
  • GlaxoSmithKline
  • Gradalis
  • Immunocore
  • Immune Design
  • Merck
  • MolMed
  • NeoStem Oncology



Skin cancer incidences are increasing at alarming rates across the world causing high morbidity and mortality. Research and development in field is expected to change the present scenario by providing better therapeutic options for patients. Skin cancer therapeutics available in market used for first-line treatment have modest efficacy which lays emphasis on the development of better products like skin cancer vaccines. Cancer vaccines for different disease indications have proved their worth in medical fraternity by providing better safety and efficacy profiles. Skin cancer vaccines based products are not available in market but they are soon expected to be entering in market in coming years. Market introduction of such products is much awaited to fulfill the unmet medical demand.

Skin cancer vaccine category seems to be one of the most advanced drug category in terms of number of products and types of products. Efforts in this field have allowed the investigators to come with new ideas like implants and oncolytic viruses for the treatment of skin cancer. Such dichotomy is not observable in other cancer categories due to which this segment is expected to occupy significant market share. Also, among different cancer products this skin cancer is expected to generate more revenues in coming years. Initially, it is expected that skin cancer vaccines would be used in combinatorial therapy with conventionally available drugs before becoming main stream treatment. Owing to better pharmacological profiles they are expected to become regular component of therapeutic regime.

Novelty of skin cancer vaccine design is expected to be the major factor in increasing their market penetration. Oncolytic skin cancer vaccines are much awaited products as they have no competitors in present market. Theoretically, they can cure skin cancer at advanced stages and increase the life span of patients but they still needs to be investigated rigorously in clinical trials before market introduction. Skeptics and many medical professional show concern about use of oncolytic viruses as they have pathogenic background and mutate to wild type causing infection in patients. However, such phenomenon has not been observed due to advanced genetic engineering and strict quality control during skin cancer vaccine production. Some of these products are at advanced phases of clinical trials meeting predefine end points for qualifying as a viable pharmacological option.

Implant section of skin cancer vaccine is also expected to make significant impact by decreasing present mortality and morbidity rates. Concept and therapeutic products using implants for treatment has been in pharmaceutical market for several decades. They tend to be more comfortable, require less visits to physicians and higher cost arbitrage coupled with improved technological advancements. This gives a notion that skin cancer vaccines implants will get higher acceptance rates as compared to oncolytic virus based products. However, it should not be compared in case of pharmacological effects because this depends on patients' medical condition and oncologists' discretion to utilize best product according to necessity.

"Global Skin Cancer Vaccine Market & Pipeline Insight 2015" Report Highlight

  • Introduction to Skin Cancer Vaccine
  • Global Skin Cancer Vaccine Market Analysis
  • Global Skin Cancer Vaccine Pipeline by Company & Phase
  • Global Skin Cancer Vaccine Pipeline: 47 Vaccines
  • Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines
  • Marketed Skin Cancer Vaccines: 2 (MVax by AVAX Technologies & Melacine by GlaxoSmithKline)
  • Personalized Cancer Vaccines: Progress & Possibilities
  • Skin Cancer Vaccine Mechanism

Table of Contents

1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations

  • 2.1 Idiotype Cancer Vaccine Mechanism
  • 2.2 Cellular Cancer Vaccines Mechanism
  • 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4 Peptide Cancer Vaccine Mechanism
  • 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Introduction to Skin Cancer Vaccine

4. Skin Cancer Vaccine Mechanism

5. Global Skin Cancer Vaccine Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Global Skin Cancer Vaccines Pipeline Overview

6. Global Skin Cancer Vaccine Market Dynamics

  • 6.1 Favorable Market Parameters
  • 6.2 Commercialization Challenges

7. Personalized Cancer Vaccines: Progress & Possibilities

8. Global Skin Cancer Vaccines Market Future Prospects

9. Global Skin Cancer Vaccine Pipeline by Company & Phase

  • 9.1 Preclinical
  • 9.2 Clinical
  • 9.3 Phase-I
  • 9.4 Phase-I/II
  • 9.5 Phase-II
  • 9.6 Phase-III

10. Marketed Skin Cancer Vaccines Clinical Analysis

  • 10.1 Melanoma Vaccine (MVax®, AVAX Technologies)
  • 10.2 Melanoma Vaccine (Melacine®, GlaxoSmithKline)

11. Suspended & Discontinued Skin Cancer Vaccines Pipeline by Company & Phase

  • 11.1 No Development Reported
  • 11.2 Discontinued

12. Competitive Landscape

  • 12.1 Amgen
  • 12.2 AVAX Technologies
  • 12.3 Corixa
  • 12.4 GlaxoSmithKline
  • 12.5 Gradalis
  • 12.6 Immunocore
  • 12.7 Immune Design
  • 12.8 Merck
  • 12.9 MolMed
  • 12.10 NeoStem Oncology

List of Figures & Tables

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 3-1: Functions of Skin
  • Figure 3-2: Layers of Skin
  • Figure 3-3: Types of Skin Cancer
  • Figure 3-4: Factors Causing Skin Cancer
  • Figure 4-1: Types of Skin Cancer Treatment
  • Figure 4-2: Implantable Skin Cancer Vaccine
  • Figure 4-3: Mechanism of Oncolytic Skin Cancer Vaccine
  • Figure 4-4: Mechanism of T-VEC Skin Cancer Vaccine
  • Figure 5-1: Global Skin Cancer Vaccines Pipeline (%), 2015
  • Figure 5-2: Global Skin Cancer Vaccines Pipeline (Number), 2015
  • Figure 5-3: No Development Reported in Skin Cancer Vaccines Pipeline (%), 2015
  • Figure 5-4: No Development Reported in Skin Cancer Vaccines Pipeline (Number), 2015
  • Figure 5-5: Discontinued Skin Cancer Vaccines in Pipeline (%), 2015
  • Figure 5-6: Discontinued Skin Cancer Vaccines in Pipeline (Number), 2015
  • Figure 6-1: Drivers for Skin Cancer Vaccine
  • Figure 6-2: Skin Cancer Vaccine Market Challenges
  • Figure 7-1: Overview of Personalized Cancer Vaccines Development
  • Figure 7-2: Methodology for the Development of Personalized Cancer Vaccine
  • Figure 7-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Back to Top